Elevated S100B levels in schizophrenia are associated with insulin resistance
Elevated S100B levels in schizophrenia are associated with insulin resistance
复制标题
精神分裂症患者 S100B 水平升高与胰岛素抵抗相关
DOI:
10.1038/mp.2009.87
复制
发表时间:
2010
影响因子:
11
通讯作者:
Bogerts B.
中科院分区:
文献类型:
--
作者:
Steiner J;Walter M;Guest P;Myint AM;Schiltz K;Panteli B;Brauner M;Bernstein H;Herberth M;Schroeter ML;Schwarz MJ;Westphal S;Bahn S;Bogerts B.
Several studies have shown that circulating S100B protein levels are elevated in schizophrenia. 1 This finding has been specifically attributed to glial pathology, as S100B is produced by astro-and oligodendroglial cells and is thought to act as a neurotrophic factor with effects on synaptogenesis, dopaminergic and glutamatergic neutrotransmission. 2 However, this study suggests that overweight and insulin resistance may be alternatively responsible. Adipose tissue has already been highlighted by others as an important extracerebral source of S100B, as it contains considerable amounts of S100B. 3, 4 S100B secretion from adipocytes is reduced by insulin and is activated by physiological factors such as stress and fasting. 5, 6 Therefore, weight gain or adipocyte dysfunction, including insulin insensitivity, could offer important alternative explanations for elevated S100B levels, given the increased prevalence of metabolic syndrome in schizophrenic patients and their firstdegree relatives. 7 The assumption of such extracerebral origins of altered S100B levels in schizophrenia is challenged by findings of elevated S100B in cerebrospinal fluid and postmortem brain tissue. 8, 9 However, glial abnormalities in S100B release may also be caused by disrupted energy supply, as suggested by earlier cell culture studies. 2 Accordingly, impaired insulin signaling has been observed in the dorsolateral prefrontal cortex of schizophrenic patients. 10 Consequently, altered peripheral and cerebral glucose usage is an important factor to be studied to clarify its relation to S100B in schizophrenia. Our study thus assessed S100B in both medicated and drug-free schizophrenic patients, along with body mass index (BMI), measures of glucose usage and adipokine levels.After obtaining written informed consent, serum samples were taken from 26 patients with acute paranoid schizophrenia (according to DSM-IV, 17 men/9 women, age 34.7±11.3 years, BMI 27.7±5.7, 16 smokers/10 nonsmokers) and from 32 matched controls (20 men/12 women, age 34.4±10.8, BMI 24.3±3.8, 14 smokers/18 nonsmokers). Eleven patients were unmedicated for X6 weeks; 15 were treated with atypical antipsychotics for 26±21 days. Psychopathology was monitored using the positive and negative syndrome scale. Exclusion criteria consisted of an earlier history of immune diseases, immunomodulating treatment, cancer, chronic terminal disease, cardiovascular disorders, diabetes, substance abuse and severe
DOI:
--
发表时间:
1983
期刊:
International Journal of Biochemistry
影响因子:
--
作者:
K. Kato;F. Suzuki;T. Nakajima
通讯作者:
T. Nakajima
影响因子:
3.3
作者:
Johann Steiner;H. Bernstein;B. Bogerts;T. Gos;C. Richter-Landsberg;M. Wunderlich;G. Keilhoff
通讯作者:
Johann Steiner;H. Bernstein;B. Bogerts;T. Gos;C. Richter-Landsberg;M. Wunderlich;G. Keilhoff
DOI:
--
发表时间:
2005
期刊:
The British journal of psychiatry : the journal of mental science
影响因子:
--
作者:
J. Thakore
通讯作者:
J. Thakore